Artivion (AORT) to Release Earnings on Thursday

Artivion (NYSE:AORT) is projected to post its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Artivion to post earnings of $0.14 per share and revenue of $110.7120 million for the quarter. Artivion has set its FY 2025 guidance at EPS.Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The business had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. The business’s revenue for the quarter was up 15.3% on a year-over-year basis. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Artivion Price Performance

Shares of NYSE:AORT opened at $45.79 on Wednesday. Artivion has a fifty-two week low of $21.97 and a fifty-two week high of $46.58. The business has a 50-day simple moving average of $42.29 and a two-hundred day simple moving average of $35.08. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -109.03 and a beta of 1.67.

Insider Buying and Selling at Artivion

In other Artivion news, insider John E. Davis sold 10,802 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total value of $471,723.34. Following the completion of the transaction, the insider directly owned 208,778 shares in the company, valued at $9,117,335.26. This represents a 4.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Marshall S. Stanton sold 18,200 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total transaction of $801,164.00. Following the completion of the transaction, the senior vice president owned 64,200 shares of the company’s stock, valued at approximately $2,826,084. The trade was a 22.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 74,858 shares of company stock worth $3,250,129 over the last 90 days. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its position in shares of Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after acquiring an additional 139,370 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Artivion by 22.8% in the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock valued at $20,062,000 after acquiring an additional 119,634 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Artivion in the 2nd quarter valued at about $2,582,000. Sei Investments Co. bought a new position in shares of Artivion in the 2nd quarter valued at about $1,627,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Artivion by 392.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 57,486 shares of the company’s stock valued at $1,788,000 after acquiring an additional 45,803 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AORT has been the topic of several research analyst reports. Canaccord Genuity Group increased their price target on Artivion from $41.00 to $50.00 and gave the company a “buy” rating in a report on Monday, September 29th. Wall Street Zen raised Artivion from a “hold” rating to a “buy” rating in a report on Monday, August 25th. Oppenheimer reaffirmed an “outperform” rating on shares of Artivion in a research report on Friday, August 8th. Stifel Nicolaus upped their price target on shares of Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, September 29th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Artivion in a research report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $43.97.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.